291 related articles for article (PubMed ID: 34587768)
41. Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.
Ruggiero A; Martora F; Picone V; Marano L; Fabbrocini G; Marasca C
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203664
[TBL] [Abstract][Full Text] [Related]
42. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.
Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156
[TBL] [Abstract][Full Text] [Related]
43. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review.
van Rappard DC; Limpens J; Mekkes JR
J Dermatolog Treat; 2013 Oct; 24(5):392-404. PubMed ID: 22397574
[TBL] [Abstract][Full Text] [Related]
44. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
Megna M; Bettoli V; Chimenti S; Chiricozzi A; Naldi L; Virgili A; Girolomoni G; Monfrecola G
G Ital Dermatol Venereol; 2015 Dec; 150(6):731-9. PubMed ID: 26513043
[TBL] [Abstract][Full Text] [Related]
45. Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review.
Schneider C; Stratman S; Choragudi S; Lev-Tov H
J Drugs Dermatol; 2023 May; 22(5):445-450. PubMed ID: 37133467
[TBL] [Abstract][Full Text] [Related]
46. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
Samycia M; Brassard A
J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
[TBL] [Abstract][Full Text] [Related]
47. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review.
Montero-Vilchez T; Pozo-Román T; Sánchez-Velicia L; Vega-Gutiérrez J; Arias-Santiago S; Molina-Leyva A
J Dermatolog Treat; 2022 Feb; 33(1):348-353. PubMed ID: 32279593
[TBL] [Abstract][Full Text] [Related]
48. Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature.
Salvatori S; Marafini I; Monteleone G
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1046-e1050. PubMed ID: 33905217
[TBL] [Abstract][Full Text] [Related]
49. Successful control of hidradenitis suppurativa with verapamil: a case report.
Laroche ML; Teste M; Vanoost J; Geniaux H
Fundam Clin Pharmacol; 2019 Feb; 33(1):122-124. PubMed ID: 30025186
[TBL] [Abstract][Full Text] [Related]
50. Systematic review of immunomodulatory therapies for hidradenitis suppurativa.
Lim SYD; Oon HH
Biologics; 2019; 13():53-78. PubMed ID: 31190730
[No Abstract] [Full Text] [Related]
51. Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa.
DeFazio MV; Economides JM; King KS; Han KD; Shanmugam VK; Attinger CE; Evans KK
Ann Plast Surg; 2016 Aug; 77(2):217-22. PubMed ID: 26559649
[TBL] [Abstract][Full Text] [Related]
52. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic.
Kearney N; Hughes R; Kirby B
Clin Exp Dermatol; 2023 Jul; 48(7):790-792. PubMed ID: 37017188
[TBL] [Abstract][Full Text] [Related]
53. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
[No Abstract] [Full Text] [Related]
54. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
[TBL] [Abstract][Full Text] [Related]
55. A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine.
Marrani E; Abu-Rumeileh S; Mastrolia MV; Maccora I; Pagnini I; Simonini G
Clin Exp Rheumatol; 2022 Feb; 40(2):457-470. PubMed ID: 34905479
[TBL] [Abstract][Full Text] [Related]
56. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.
Zouboulis CC; Bechara FG; Dickinson-Blok JL; Gulliver W; Horváth B; Hughes R; Kimball AB; Kirby B; Martorell A; Podda M; Prens EP; Ring HC; Tzellos T; van der Zee HH; van Straalen KR; Vossen ARJV; Jemec GBE
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):19-31. PubMed ID: 30176066
[TBL] [Abstract][Full Text] [Related]
57. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study.
Prens LM; Bouwman K; Aarts P; Arends S; van Straalen KR; Dudink K; Horváth B; Prens EP
Br J Dermatol; 2021 Jul; 185(1):177-184. PubMed ID: 33544917
[TBL] [Abstract][Full Text] [Related]
58. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
Batu ED; Sener S; Cam V; Aktay Ayaz N; Ozen S
BioDrugs; 2023 Nov; 37(6):813-828. PubMed ID: 37382804
[TBL] [Abstract][Full Text] [Related]
59. Effect of Biologics on the Need for Procedural Interventions, Systemic Medications, and Healthcare Utilization in Patients with Hidradenitis Suppurativa: Real-World Data from the UNITE Registry.
Oliveira M; Rahawi K; Duan Y; Lane M; Amin AZ; Sayed CJ
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1577-1585. PubMed ID: 37314696
[TBL] [Abstract][Full Text] [Related]
60. Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective.
Heidari A; Ghane Y; Heidari N; Hosseini S; Goodarzi A
Ther Adv Chronic Dis; 2024; 15():20406223241257342. PubMed ID: 38827348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
